The CER sales growth of 5% was buoyed by a 15% currency tailwind, translating into sales of £7.4bn in Q1. Growth, despite the 1.5% negative impact from the disposals of Aspen and Romanian distribution, was spread across CER growth of 4% (+17% reported) in pharma, 16% (+31% reported) in vaccines and 2% (+16% reported) in consumer health. NB All revenue growth numbers in CER unless specified otherwise. Within pharma, respiratory (40% of pharma) grew by 5%, HIV (23% of pharma) by 19%, Immu
03 Jul 2017
Brexit on the cake
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Brexit on the cake
GSK plc (GSK:LON) | 1,583 -102.9 (-0.4%) | Mkt Cap: 65,603m
- Published:
03 Jul 2017 -
Author:
Kamla Singh -
Pages:
4
The CER sales growth of 5% was buoyed by a 15% currency tailwind, translating into sales of £7.4bn in Q1. Growth, despite the 1.5% negative impact from the disposals of Aspen and Romanian distribution, was spread across CER growth of 4% (+17% reported) in pharma, 16% (+31% reported) in vaccines and 2% (+16% reported) in consumer health. NB All revenue growth numbers in CER unless specified otherwise. Within pharma, respiratory (40% of pharma) grew by 5%, HIV (23% of pharma) by 19%, Immu